Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reformulated BeneFIX Efficacy After pdFIX Switch
NCT00749476Phase 4Completed
- Sponsor
- Pfizer
- Start
- Apr 2008
- Primary completion
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of coagulation factor ix recombinant in hemophilia B (HB), sponsored by Pfizer. Primary endpoint: Number of Participants Reporting Efficacy at 4 months. Started Apr 2008; status: completed.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT00749476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00749476.